Yes, looks like a push to secure financing until t
Post# of 154797
(Total Views: 445)
Posted On: 09/21/2019 11:54:23 AM
Yes, looks like a push to secure financing until the end of the year. To
1) Get rid of Paulson
2) finish the BLA
3) time to finish deals without pressure of finances
Get the financing to finish the BLA and financing deals to support the company past the BLA submission.
So if they get this financing secured, NP gets until the end of the year worst case to get these done: BLA, partnerships. At that point, if he can't get it done, no more excuses, it is time for someone else that can imo.
Burn rate? The current mono trial is probably burning 2-3M per month. The meeting with fda approves pivotal mono trial, shut that one done if allowed. The BLA is burning probably $1-2M per month. The significance of finishing the BLA is technically the could have the burn rate under $1M per month or less if they didn't pay salaries. The significance of the BLA submission with that technically they could push the burn rate to almost zero after submission until drug approval. But they need the cash to get the BLA submission done
Non-accredited investors participating: Some direct offerings this, I'm not sure what they are filing under with this offering or if it is allowed. For example, "Under Rule 506, an issuer can sell securities to an unlimited amount of accredited investors and up to 35 non-accredited investors."
1) Get rid of Paulson
2) finish the BLA
3) time to finish deals without pressure of finances
Get the financing to finish the BLA and financing deals to support the company past the BLA submission.
So if they get this financing secured, NP gets until the end of the year worst case to get these done: BLA, partnerships. At that point, if he can't get it done, no more excuses, it is time for someone else that can imo.
Burn rate? The current mono trial is probably burning 2-3M per month. The meeting with fda approves pivotal mono trial, shut that one done if allowed. The BLA is burning probably $1-2M per month. The significance of finishing the BLA is technically the could have the burn rate under $1M per month or less if they didn't pay salaries. The significance of the BLA submission with that technically they could push the burn rate to almost zero after submission until drug approval. But they need the cash to get the BLA submission done
Non-accredited investors participating: Some direct offerings this, I'm not sure what they are filing under with this offering or if it is allowed. For example, "Under Rule 506, an issuer can sell securities to an unlimited amount of accredited investors and up to 35 non-accredited investors."
(2)
(0)